Close Menu

NEW YORK (GenomeWeb) – Promega said today that it has non-exclusively licensed the Broad Institute's CRISPR-Cas9 intellectual property.

Under the terms of the agreement, Promega will combine the Broad's CRISPR-Cas9 technology with its own products for knock-in of genetic reporters into the genomes of any cell or cell line. The firm is aiming to develop and sell gene editing tools and reagents for interrogating endogenous biology at physiologically relevant expression levels.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.